IN2015DN03751A - - Google Patents
Info
- Publication number
- IN2015DN03751A IN2015DN03751A IN3751DEN2015A IN2015DN03751A IN 2015DN03751 A IN2015DN03751 A IN 2015DN03751A IN 3751DEN2015 A IN3751DEN2015 A IN 3751DEN2015A IN 2015DN03751 A IN2015DN03751 A IN 2015DN03751A
- Authority
- IN
- India
- Prior art keywords
- substituted
- pyrimidine
- isothiazolo
- monocyclic
- organ
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical class C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 abstract 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 230000000771 oncological effect Effects 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 abstract 1
- 150000003230 pyrimidines Chemical group 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1217704.4A GB201217704D0 (en) | 2012-10-03 | 2012-10-03 | Therapeutic agents |
| PCT/EP2013/070600 WO2014053581A1 (fr) | 2012-10-03 | 2013-10-02 | Dérivés d'oxazoline thérapeutiquement actifs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN03751A true IN2015DN03751A (fr) | 2015-10-02 |
Family
ID=47225621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3751DEN2015 IN2015DN03751A (fr) | 2012-10-03 | 2013-10-02 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9382263B2 (fr) |
| EP (1) | EP2903990B1 (fr) |
| JP (1) | JP6184501B2 (fr) |
| CN (1) | CN104936962B (fr) |
| BR (1) | BR112015007503A2 (fr) |
| CA (1) | CA2886265A1 (fr) |
| ES (1) | ES2639293T3 (fr) |
| GB (1) | GB201217704D0 (fr) |
| IN (1) | IN2015DN03751A (fr) |
| RU (1) | RU2656209C2 (fr) |
| WO (1) | WO2014053581A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016081732A1 (fr) | 2014-11-19 | 2016-05-26 | Memorial Sloan-Kettering Cancer Center | Thiénopyrimidines et utilisations de celles-ci |
| AR104020A1 (es) * | 2015-06-04 | 2017-06-21 | Kura Oncology Inc | Métodos y composiciones para inhibir la interacción de menina con proteínas mill |
| GB201517263D0 (en) | 2015-09-30 | 2015-11-11 | Ucb Biopharma Sprl And Katholieke Universiteit Leuven | Therapeutic agents |
| GB201521767D0 (en) | 2015-12-10 | 2016-01-27 | Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R&D | Therapeutic agents |
| RS64261B1 (sr) | 2016-03-16 | 2023-07-31 | Kura Oncology Inc | Supstituisani derivati tieno[2,3-d]pirimidina kao inhibitori menin-mll i načini upotrebe |
| EP3601249A4 (fr) | 2017-03-24 | 2020-12-16 | Kura Oncology, Inc. | Méthodes de traitement d'hémopathies malignes et du sarcome d'ewing |
| US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| US11649251B2 (en) | 2017-09-20 | 2023-05-16 | Kura Oncology, Inc. | Substituted inhibitors of menin-MLL and methods of use |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2408396A1 (fr) * | 2000-04-17 | 2001-10-25 | Basf Aktiengesellschaft | Composes de benzisoxazole et de benzisothiazole substitute en 3 positions par un heterocycle herbicides |
| WO2005021552A1 (fr) * | 2003-08-29 | 2005-03-10 | Vernalis (Cambridge) Ltd | Composes pyrimidothiophene |
| CA2602538A1 (fr) * | 2005-03-28 | 2006-10-05 | Pharmacia & Upjohn Company Llc | Derives de 4-piperazinothieno[2, 3-d]pyrimidine en tant qu'agents inhibiteurs de l'agregation de plaquettes sanguines |
| TW201024307A (en) * | 2008-09-10 | 2010-07-01 | Kalypsys Inc | Aminopyrimidine inhibitors of histamine receptors for the treatment of disease |
| ES2665277T3 (es) * | 2009-03-13 | 2018-04-25 | Katholieke Universiteit Leuven K.U. Leuven R&D | Análogos de purina y su uso como agentes inmunosupresores |
| CA2773131C (fr) * | 2009-09-04 | 2015-07-14 | The Regents Of The University Of Michigan | Compositions et methodes de traitement de la leucemie |
| GB201012889D0 (en) | 2010-08-02 | 2010-09-15 | Univ Leuven Kath | Antiviral activity of novel bicyclic heterocycles |
| GB201015411D0 (en) | 2010-09-15 | 2010-10-27 | Univ Leuven Kath | Anti-cancer activity of novel bicyclic heterocycles |
| GB201114212D0 (en) * | 2011-08-18 | 2011-10-05 | Ucb Pharma Sa | Therapeutic agents |
| GB201119401D0 (en) * | 2011-11-10 | 2011-12-21 | Ucb Pharma Sa | Therapeutic agents |
-
2012
- 2012-10-03 GB GBGB1217704.4A patent/GB201217704D0/en not_active Ceased
-
2013
- 2013-10-02 JP JP2015535015A patent/JP6184501B2/ja not_active Expired - Fee Related
- 2013-10-02 EP EP13776992.3A patent/EP2903990B1/fr active Active
- 2013-10-02 BR BR112015007503A patent/BR112015007503A2/pt not_active Application Discontinuation
- 2013-10-02 CN CN201380061725.5A patent/CN104936962B/zh not_active Expired - Fee Related
- 2013-10-02 CA CA 2886265 patent/CA2886265A1/fr not_active Abandoned
- 2013-10-02 US US14/432,842 patent/US9382263B2/en not_active Expired - Fee Related
- 2013-10-02 RU RU2015116643A patent/RU2656209C2/ru not_active IP Right Cessation
- 2013-10-02 IN IN3751DEN2015 patent/IN2015DN03751A/en unknown
- 2013-10-02 ES ES13776992.3T patent/ES2639293T3/es active Active
- 2013-10-02 WO PCT/EP2013/070600 patent/WO2014053581A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| RU2656209C2 (ru) | 2018-06-01 |
| WO2014053581A1 (fr) | 2014-04-10 |
| CA2886265A1 (fr) | 2014-04-10 |
| US9382263B2 (en) | 2016-07-05 |
| JP2015531388A (ja) | 2015-11-02 |
| EP2903990B1 (fr) | 2017-06-14 |
| JP6184501B2 (ja) | 2017-08-23 |
| GB201217704D0 (en) | 2012-11-14 |
| EP2903990A1 (fr) | 2015-08-12 |
| ES2639293T3 (es) | 2017-10-26 |
| BR112015007503A2 (pt) | 2017-07-04 |
| CN104936962B (zh) | 2017-02-22 |
| RU2015116643A (ru) | 2016-11-27 |
| CN104936962A (zh) | 2015-09-23 |
| US20150274748A1 (en) | 2015-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN03751A (fr) | ||
| MY189182A (en) | Therapeutically active pyrazolo-pyrimidine derivatives | |
| BR112016011484A2 (pt) | Derivados de imidazopirimidina como moduladores de atividade de tnf | |
| WO2013024291A3 (fr) | Dérivés de pyrimidine fusionnés à activité thérapeutique | |
| BR112014008865A2 (pt) | imidazo[1,2-c]pirimidinas 5,7-substituídas | |
| UA115677C2 (uk) | ПОХІДНІ ПІРОЛО[3,2-d]ПІРИМІДИНУ ДЛЯ ЛІКУВАННЯ ВІРУСНИХ ІНФЕКЦІЙ ТА ІНШИХ ЗАХВОРЮВАНЬ | |
| IL229193A0 (en) | The history of pyridine-2--(h1) and its effectiveness as drugs for the treatment of myeloproliferative disorders, graft rejection, and infectious and immune-mediated diseases | |
| CO6440524A2 (es) | Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la quinasa janus. | |
| IN2014CN03597A (fr) | ||
| PH12012502046A1 (en) | 5,7-substituted~imidazo[1,2-c]pyrimidines as inhibitors of jak kinases | |
| EA202090258A3 (ru) | Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний | |
| BR112016011485A2 (pt) | Derivados de imidazopiridazina como moduladores de atividade de tnf | |
| BR112016011527A2 (pt) | Derivados de imidazopiridina como moduladores de atividade de tnf | |
| BR112016012254A2 (pt) | Derivados de triazolpiridazina como moduladores de atividade de tnf | |
| BR112016029632A2 (pt) | derivados heteroaromáticos bicíclicos fundidos como inibidores de cinase | |
| IL246034B (en) | History of [1,2,4]triazolo[1,5-a]pyrimidine as protozoan proteasome inhibitors for the treatment of parasitic diseases such as Jericho | |
| EA201890826A1 (ru) | Конденсированные производные пиридина в качестве ингибиторов киназы | |
| EA201891349A1 (ru) | Производные гексагидропиразинотриазинона в качестве ингибиторов киназы | |
| UA114825C2 (uk) | Терапевтично активні похідні піразолопіримідину | |
| ECSP15031293A (es) | Derivados de pirazolo-pirimidina terapeuticamente activos | |
| HK1196600A (en) | Pyridin-2 (1h) -one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases | |
| ECSP11011535A (es) | Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la quinasa janus |